Salud financiera de hoja de balance de Pacific Biosciences of California
Salud financiera controles de criterios 2/6
Pacific Biosciences of California tiene un patrimonio de los accionistas total de $453.1M y una deuda total de $893.1M, lo que sitúa su ratio deuda-patrimonio en 197.1%. Sus activos y pasivos totales son $1.5B y $996.9M respectivamente.
Información clave
197.1%
Ratio deuda-patrimonio
US$893.14m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$471.15m |
| Patrimonio | US$453.12m |
| Total pasivo | US$996.93m |
| Activos totales | US$1.45b |
Actualizaciones recientes sobre salud financiera
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Recent updates
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Nov 12Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company
Nov 07Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely
Sep 20Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
Aug 21Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper
Jul 02We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas
Jun 03These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat
Apr 25It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?
Jul 31Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Jul 06Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt
May 25Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?
Mar 29Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?
Feb 26Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($585.8M) de PACB superan a sus pasivos a corto plazo ($31.2M).
Pasivo a largo plazo: Los activos a corto plazo ($585.8M) de PACB no cubren sus pasivos a largo plazo ($965.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de PACB (93.1%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de PACB ha crecido de 30.5% a 197.1% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: PACB tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si PACB tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.